Jonathan W. Goldman, MD, discusses management of the most common adverse events associated with osimertinib in patients with non–small cell lung cancer.
Jonathan W. Goldman, MD, associate professor of medicine in the hematology/oncology division, director of clinical trials in thoracic oncology, and the associate director of early drug development at UCLA Health, discusses management of the most common adverse events (AEs) associated with osimertinib (Tagrisso) in patients with non–small cell lung cancer.
Goldman says that osimertinib is generally well tolerated compared with other agents in this space. It has less incidence of severe rash than the previously used EGFR inhibitors erlotinib (Tarceva) and gefitinib (Iressa), which osimertinib was compared with in the FLAURA trial (NCT02296125).
Approximately 10% of patients require supportive care for diarrhea; Goldman suggests giving patients loperamide (Imodium) and making sure they have it on hand. Paronychia infecting the skin of the fingers or toes can be another challenge. He says a podiatrist can be consulted for paronychia of the feet and they are often effective at controlling this toxicity. For the hands or in general, patients can manage paronychia with moisturizer, or soak with saltwater Epsom salts. They can also cover the area affected or use ointment such as petroleum jelly.
TRANSCRIPTION:
0:08 | Osimertinib is in general an easy therapy for most patients to tolerate in the metastatic setting.... Compared [with] other EGFR inhibitors, we tend to see less rash and that was really the most significant challenge for most patients on the previous drugs erlotinib or gefitinib, so that was a welcome change.
We still do see diarrhea that needs management in about 10% of patients. There we use typically loperamide for patients and I often ask patients to have it on hand, especially if they're leaving town or something like that, so they're ready to treat that.
0:53 | Paronychia can be challenging, sometimes painful and difficult in some circumstances to completely control. If there's any paronychia of the feet, I do very frequently get a podiatrist involved; they're often very successful at treating it. Of the hands, sometimes not quite the same opportunity to get other specialists involved, but keeping the hands off with a moisturizer, sometimes, saltwater [or] Epsom salt soaks can be helpful; Band-Aids and covering the area if it gets particularly inflamed, and occlusive ointment, as simple as Vaseline or something with antibiotics can be helpful as well. And those are really the most common [AEs] that we see.
Patient Preference Plays Limited Role in Selection of Therapy for Melanoma
May 17th 2024During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants whether factors such as patient preference influence their choice of melanoma treatment in the second article of a 2-part series.
Read More
Discussing Non-Clinical Barriers to NGS Testing for NSCLC
May 15th 2024During a Case-Based Roundtable® event, Julia Rotow, MD, led a discussion on the non-clinical barriers that impact the use of using next-generation sequencing for patients with certain mutations of their non–small cell lung cancer in the first article of a 2-part series.
Read More
Lower-Dose Selinexor Data Lead to Patient Selection Questions in RRMM
May 14th 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Read More
Experience and Sequencing Guide Third-Line DLBCL Therapy Selection
May 13th 2024During a Case-Based Roundtable® event, Matthew Ulrickson, MD, discussed experiences with loncastuximab and other targeted treatments in patients with diffuse large B-cell lymphoma with event participants in the first article of a 2-part series.
Read More